首页> 外文期刊>International Journal of Biological Macromolecules: Structure, Function and Interactions >Chitosan coated liposomes (CCL) containing triamcinolone acetonide for sustained delivery: A potential topical treatment for posterior segment diseases
【24h】

Chitosan coated liposomes (CCL) containing triamcinolone acetonide for sustained delivery: A potential topical treatment for posterior segment diseases

机译:壳聚糖涂覆的脂质体(CCL)含有抗菊酮酮丙酮酮,用于持续递送:对后部疾病的潜在局部处理

获取原文
获取原文并翻译 | 示例
       

摘要

Drug delivery to the posterior eye is limited by epithelial and mucosal barriers limiting the topical administration of drugs leading to invasive modes of repeated long-term painful administration of drugs. Several constructs of liposomes have been prepared to counter this challenge yet are often limited by size and surface charge resulting in poor encapsulation efficiency, low retention time, and poor permeability. In the present study, chitosan coated liposomes (CCL) were prepared to address these challenges. Conventional liposomes encapsulating Triamcinolone Acetonide (TA) were compared with their chitosan coated counterpart for drug loading and release studies. CCL showed a higher encapsulation efficiency (74%), and a highly positive surface charge (+41.1Mv), increased retention time and sustained release. Choroidal neovascularization (CNV) rat models were generated to assess the efficiency of CCLs as nanocarriers in drug delivery. Significant amount of TA was found to be present and retaining in the eye after fifteen days of treatment with CCL, as shown by HPLC analysis. The results showed successful penetration of the construct via corneal mucosal barrier and its accumulation in vitreous body. The analysis shows that this chitosan based liposomal construct can be employed as a potential topical delivery system for treating posterior segment diseases. (C) 2019 Elsevier B.V. All rights reserved.
机译:后眼药递送的药物递送是限制的上皮和粘膜屏障,限制了药物的局部施用,导致重复长期痛苦药物的侵入方式。已经制备了几种脂质体的构建体以对抗这种挑战,但通常受到尺寸和表面电荷的限制,导致封装效率不良,低保留时间和渗透性差。在本研究中,制备壳聚糖涂覆的脂质体(CCL)以解决这些挑战。将常规的脂质体包封脂肪糖酮醋酸酮酮(TA)与其壳聚糖涂覆的对应物进行比较用于药物载体和释放研究。 CCL显示出较高的封装效率(74%),高度阳性表面电荷(+ 41.1mV),增加保留时间和持续释放。产生脉络膜新生血管(CNV)大鼠模型,以评估CCLS作为药物递送中纳米载体的效率。用CCl处理十五天后,发现大量的TA在眼睛中存在并保持在眼睛中,如HPLC分析所示。结果表明,通过角膜粘膜屏障和玻璃体中的积聚成功地渗透。分析表明,该基于壳聚糖基脂质体构建体可用作治疗后部疾病的潜在局部输送系统。 (c)2019 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号